Details for New Drug Application (NDA): 214102
✉ Email this page to a colleague
NDA 214102 describes VALSARTAN, which is a drug marketed by Novitium Pharma, Alembic, Alkem Labs Ltd, Amneal Pharms, Aurobindo Pharma Ltd, Dr Reddys, Hetero Labs Ltd V, Ivax Pharms, Jubilant Generics, Lupin Ltd, Macleods Pharms Ltd, Mylan, Ohm Labs Inc, Prinston Inc, Sciegen Pharms Inc, Square Pharms, Torrent, Unichem, Watson Labs Inc, Zenara, Zydus Lifesciences, Apotex Inc, Mylan Pharms Inc, and Watson Labs Teva, and is included in thirty-one NDAs. It is available from thirty-four suppliers. Additional details are available on the VALSARTAN profile page.
The generic ingredient in VALSARTAN is hydrochlorothiazide; valsartan. There are thirty-two drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; valsartan profile page.
The generic ingredient in VALSARTAN is hydrochlorothiazide; valsartan. There are thirty-two drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; valsartan profile page.
Summary for 214102
| Tradename: | VALSARTAN |
| Applicant: | Novitium Pharma |
| Ingredient: | valsartan |
| Patents: | 0 |
Pharmacology for NDA: 214102
| Mechanism of Action | Angiotensin 2 Receptor Antagonists |
Medical Subject Heading (MeSH) Categories for 214102
Suppliers and Packaging for NDA: 214102
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| VALSARTAN | valsartan | SOLUTION;ORAL | 214102 | ANDA | ANI Pharmaceuticals, Inc. | 70954-310 | 70954-310-10 | 120 mL in 1 BOTTLE, PLASTIC (70954-310-10) |
| VALSARTAN | valsartan | SOLUTION;ORAL | 214102 | ANDA | ANI Pharmaceuticals, Inc. | 70954-310 | 70954-310-20 | 473 mL in 1 BOTTLE, PLASTIC (70954-310-20) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;ORAL | Strength | 20MG/5ML | ||||
| Approval Date: | Nov 2, 2021 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
